World's Best Scientists 2026 revealed!

D-Index & Metrics

Psychology

D-Index
40
Citations
10887
World Ranking
8081
National Ranking
4329

Robert Goldman publication distribution in Psychology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Psychology in 2026. The highlighted bar marks where Robert Goldman sits on this spectrum.

31–40 publications: 6 scientists 41–50 publications: 52 scientists 51–60 publications: 138 scientists 61–70 publications: 299 scientists 71–80 publications: 461 scientists 81–90 publications: 605 scientists 91–100 publications: 713 scientists 101–110 publications: 736 scientists 111–120 publications: 686 scientists 121–130 publications: 670 scientists 131–140 publications: 644 scientists 141–150 publications: 597 scientists 151–160 publications: 576 scientists 161–170 publications: 477 scientists 171–180 publications: 450 scientists 181–190 publications: 397 scientists 191–200 publications: 343 scientists 201–210 publications: 328 scientists 211–220 publications: 313 scientists 221–230 publications: 283 scientists 231–240 publications: 226 scientists 241–250 publications: 196 scientists 251–260 publications: 201 scientists 261–270 publications: 171 scientists 271–280 publications: 151 scientists 281–290 publications: 139 scientists 291–300 publications: 113 scientists 301–310 publications: 102 scientists 311–320 publications: 100 scientists 321–330 publications: 76 scientists 331–340 publications: 92 scientists 341–350 publications: 85 scientists 351–360 publications: 69 scientists 361–370 publications: 71 scientists 371–380 publications: 63 scientists 381–390 publications: 58 scientists 391–400 publications: 57 scientists 401–410 publications: 43 scientists 411–420 publications: 33 scientists 421–430 publications: 50 scientists 431–440 publications: 41 scientists 441–450 publications: 32 scientists 451–460 publications: 27 scientists 461–470 publications: 28 scientists 471–480 publications: 25 scientists 481–490 publications: 28 scientists 491–500 publications: 20 scientists 501–510 publications: 23 scientists 511–520 publications: 26 scientists 521–530 publications: 17 scientists 531–540 publications: 21 scientists 541–550 publications: 14 scientists 551–560 publications: 16 scientists 561–570 publications: 10 scientists 571–580 publications: 22 scientists 581–590 publications: 9 scientists 591–600 publications: 14 scientists 601–610 publications: 9 scientists 611–620 publications: 11 scientists 621–630 publications: 4 scientists 631–640 publications: 7 scientists 641–650 publications: 5 scientists 651–660 publications: 10 scientists 661–670 publications: 8 scientists 671–680 publications: 8 scientists 681–690 publications: 4 scientists 691–700 publications: 3 scientists 701–704 publications: 4 scientists 705+ publications: 100 scientists
31 publications 705+

This scientist: 185 publications — 64th percentile

64% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 705 publications or more.

Robert Goldman D-index placement in Psychology in 2026

The chart shows the D-index (discipline H-index) distribution of Psychology scientists ranked by Research.com in 2026. The highlighted bar marks where Robert Goldman sits on this spectrum.

30–31 D-Index: 398 scientists 32–33 D-Index: 702 scientists 34–35 D-Index: 671 scientists 36–37 D-Index: 659 scientists 38–39 D-Index: 641 scientists 40–41 D-Index: 671 scientists 42–43 D-Index: 617 scientists 44–45 D-Index: 558 scientists 46–47 D-Index: 495 scientists 48–49 D-Index: 487 scientists 50–51 D-Index: 445 scientists 52–53 D-Index: 390 scientists 54–55 D-Index: 408 scientists 56–57 D-Index: 345 scientists 58–59 D-Index: 325 scientists 60–61 D-Index: 321 scientists 62–63 D-Index: 248 scientists 64–65 D-Index: 290 scientists 66–67 D-Index: 218 scientists 68–69 D-Index: 219 scientists 70–71 D-Index: 215 scientists 72–73 D-Index: 183 scientists 74–75 D-Index: 169 scientists 76–77 D-Index: 132 scientists 78–79 D-Index: 137 scientists 80–81 D-Index: 120 scientists 82–83 D-Index: 112 scientists 84–85 D-Index: 86 scientists 86–87 D-Index: 101 scientists 88–89 D-Index: 83 scientists 90–91 D-Index: 77 scientists 92–93 D-Index: 70 scientists 94–95 D-Index: 78 scientists 96–97 D-Index: 58 scientists 98–99 D-Index: 53 scientists 100–101 D-Index: 57 scientists 102–103 D-Index: 48 scientists 104–105 D-Index: 53 scientists 106–107 D-Index: 46 scientists 108–109 D-Index: 24 scientists 110–111 D-Index: 35 scientists 112–113 D-Index: 27 scientists 114–115 D-Index: 32 scientists 116–117 D-Index: 31 scientists 118–119 D-Index: 22 scientists 120–121 D-Index: 16 scientists 122–123 D-Index: 24 scientists 124–125 D-Index: 18 scientists 126–127 D-Index: 11 scientists 128–129 D-Index: 19 scientists 130–131 D-Index: 10 scientists 132–133 D-Index: 16 scientists 134–135 D-Index: 10 scientists 136–137 D-Index: 12 scientists 138–139 D-Index: 8 scientists 140–141 D-Index: 5 scientists 142–143 D-Index: 12 scientists 144+ D-Index: 98 scientists
30 D-Index 144+

This scientist: 40 D-Index — 30th percentile

30% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 144 D-Index or more.

Overview

Robert Goldman is affiliated with Sunovion in the United States and has contributed significantly to research in medicine and psychology. Their work primarily focuses on psychiatry and mental health, clinical psychology, and related subfields. The scientist's publications cover areas such as bipolar disorder and treatment, schizophrenia research and treatment, attention deficit hyperactivity disorder, eating disorders and behaviors, pharmaceutical studies and practices, obsessive-compulsive spectrum disorders, and the influence of neurotransmitter receptors on behavior.

Goldman has published extensively in the following venues:

  • CNS Spectrums
  • European Psychiatry
  • New England Journal of Medicine
  • Schizophrenia
  • The Journal of Clinical Psychiatry

Their recent prominent papers include:

  • A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia, 2020, New England Journal of Medicine
  • Safety and Effectiveness of Ulotaront (SEP-363856) in Schizophrenia: Results of a 6-Month, Open-Label Extension Study, 2021, Schizophrenia
  • Efficacy and Safety of Dasotraline in Adults With Binge-Eating Disorder, 2020, The Journal of Clinical Psychiatry
  • Efficacy and Safety of Dasotraline in Adults with Binge-Eating Disorder: A Randomized, Placebo-Controlled, Fixed-Dose Clinical Trial, 2020, CNS Spectrums
  • Safety and Effectiveness of SEP−363856 in Schizophrenia: Results of a 6-Month, Open-Label Extension Study, 2021, CNS Spectrums

Goldman frequently collaborates with several co-authors, including:

  • Andrei Pikalov
  • Michael Tocco
  • Antony Loebel
  • Kenneth S. Koblan
  • Justine Kent

The main fields of study for Goldman's research are medicine, with a focus on psychiatric conditions, and psychology, with specific emphasis on mental health issues. Their work intersects multiple clinical and molecular disciplines addressing complex neuropsychiatric disorders.

The scientist's publication record shows a consistent engagement with research topics that include bipolar disorder, schizophrenia, attention deficit hyperactivity disorder, eating disorders, and the neurological mechanisms influencing behavior. Their contributions provide data on clinical treatments and pharmaceutical interventions for these conditions.

Best Publications

  • Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder.

    Delbert Robinson;Margaret G. Woerner;Jose Ma. J. Alvir;Robert Bilder

  • Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates.

    Robert M. Bilder;Robert S. Goldman;Delbert Robinson;Gail Reiter

  • Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder

    Robert M. Bilder;Robert S. Goldman;Jan Volavka;Pal Czobor

  • Predictors of Treatment Response From a First Episode of Schizophrenia or Schizoaffective Disorder

    Delbert G. Robinson;Margaret G. Woerner;Jose Ma.J. Alvir;Stephen Geisler

  • Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?

    Terry E. Goldberg;Robert S. Goldman;Katherine E. Burdick;Anil K. Malhotra

  • Neurocognitive correlates of the COMT Val158Met polymorphism in chronic schizophrenia

    Robert M. Bilder;Jan Volavka;Pál Czobor;Anil K. Malhotra

  • Efficacy of donepezil in mild cognitive impairment A randomized placebo-controlled trial

    S Salloway;S Ferris;A Kluger;R Goldman

  • Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial.

    Ben Seltzer;Parvaneh Zolnouni;Margarita Nunez;Robert Goldman

  • A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia

    Kenneth S Koblan;Justine Kent;Seth C Hopkins;John H Krystal

  • Meta-analysis of symptom factors in schizophrenia

    Bret S. Grube;Robert M. Bilder;Robert M. Bilder;Robert M. Bilder;Robert S. Goldman

  • Auditory Sensory Dysfunction in Schizophrenia: Imprecision or Distractibility?

    Esther F. Rabinowicz;Gail Silipo;Robert Goldman;Daniel C. Javitt

  • Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder

    Serge Sevy;Delbert G. Robinson;Scott Holloway;Jose M. Alvir

  • Dexamethasone suppression test in schizophrenia: Relationship to symptomatology, ventricular enlargement, and outcome

    Rajiv Tandon;Cheryl Mazzara;John R. DeQuardo;Katherine A. Craig

  • Cognitive Development in Schizophrenia: Follow-Back from the First Episode

    Robert M. Bilder;Gail Reiter;Jay Bates;Todd Lencz

  • Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial.

    Richard S E Keefe;Anil K Malhotra;Herbert Y Meltzer;John M Kane

  • Circumstances Under Which Practice Does Not Make Perfect: A Review of the Practice Effect Literature in Schizophrenia and Its Relevance to Clinical Treatment Studies

    Terry E Goldberg;Richard S E Keefe;Robert S Goldman;Delbert G Robinson

  • Discriminability of the Wisconsin Card Sorting Test using the standardization sample.

    Bradley N. Axelrod;Robert S. Goldman;Robert K. Heaton;Glenn Curtiss

  • VALIDATION OF THE 16-ITEM NEGATIVE SYMPTOM ASSESSMENT

    Bradley N. Axelrod;Robert S. Goldman;Robert S. Goldman;Larry D. Alphs;Larry D. Alphs;Larry D. Alphs

  • Neuropsychological correlates of hippocampal volumes in patients experiencing a first episode of schizophrenia.

    Philip R. Szeszko;Rael D. Strous;Robert S. Goldman;Manzar Ashtari

  • Reduced anterior cingulate gyrus volume correlates with executive dysfunction in men with first-episode schizophrenia☆

    Philip R. Szeszko;Philip R. Szeszko;Robert M. Bilder;Robert M. Bilder;Robert M. Bilder;Todd Lencz;Manzar Ashtari

  • Efficacy and Safety of Lurasidone in Children and Adolescents With Bipolar I Depression: A Double-Blind, Placebo-Controlled Study

    Melissa P. DelBello;Robert Goldman;Debra Phillips;Ling Deng

Frequent Co-Authors

Robert M. Bilder
Robert M. Bilder University of California, Los Angeles
Rajiv Tandon
Rajiv Tandon Western Michigan University
Bradley N. Axelrod
Bradley N. Axelrod United States Department of Veterans Affairs
Stanley Berent
Stanley Berent University of Michigan–Ann Arbor
Jeffrey A. Lieberman
Jeffrey A. Lieberman Columbia University
John M. Kane
John M. Kane Zucker Hillside Hospital
Stephan F. Taylor
Stephan F. Taylor University of Michigan–Ann Arbor
Christoph U. Correll
Christoph U. Correll Charité - University Medicine Berlin
Katherine E. Burdick
Katherine E. Burdick Brigham and Women's Hospital
Leslie Citrome
Leslie Citrome New York Medical College

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

As you consider studying Psychology in the USA, you may also want to explore related online degrees in fields like Social Work. Earning a degree in Social Work can provide additional career pathways, such as counseling, case management, and community outreach positions. These professions often overlap with psychology, especially for those interested in helping individuals and families overcome challenges.

There are many high-quality online Social Work programs available across the country. For example, students seeking flexibility and regional focus might consider the top online social work programs in Ohio or the top online social work programs in Texas. Those researching a wider range of options can look into the best online social work degree programs in America for a national perspective.

For those interested in a local approach within specific communities, exploring the best online social work programs in Waco can be particularly useful. Each of these online degree programs can open diverse career pathways and complement a background in psychology.

Best Scientists Citing Robert Goldman

Trending Scientists

Recently Published Articles